Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 3, 2009, Pages 935-944

  Karlsson, Mats O ^a   Lutsar, Irja ^b,c   Milligan, Peter A ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c UNIVERSITY OF TARTU   (Estonia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; VORICONAZOLE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; GENOTYPE; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEWBORN; POPULATION RESEARCH; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFUSIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PYRIMIDINES; TRIAZOLES;

EID: 62949105433     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00751-08     Document Type: Article

References (25)

1. Aarons, L., J. W. Mandema, and M. Danhof. 1991. A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat. J. Pharmacokinet. Biopharm. 19:485-496.
2. Beal, S. L., and L. B. Sheiner (ed.). 1992. NONMEM users guides 1-VII1. NONMEM Project Group, University of California San Francisco (UCSF), San Francisco, CA.
3. Carillo, A. J., and J. Guarro. 2001. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob. Agents Chemother. 45:2151-2153.
4. Chandrasekar, P. H., and E. Manavathu. 2001. Voriconazole: a second- generation triazole. Drugs Today 37:135-148.
5. Graves, D. A., and I. Chang. 1990. Application of NONMEM to routine bioavailability data. J. Pharmacokinet. Biopharm. 18:145-160.
6. Groll, A. H., S. C. Piscitelli, and T. J. Walsh. 1998. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv. Pharmacol. 44:343-500.
7. Hyland, R., B. C. Jones, and D. A. Smith. 2003. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab. Dispos. 31:540-547.
8. Jonsson, E. N., and M. O. Karlsson. 1999. Xpose-an SPLUS based popu lation pharmacokinetic-pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58:51-64.
9. Jonsson, E. N., J. R. Wade, and M. O. Karlsson. 2000. Nonlinearity detection: advantages of nonlinear mixed-effects modeling. AAPS PharmSci 2:E32.
10. Karlsson, M. O., E. N. Jonsson, C. G. Wiltse, and J. R. Wade. 1998. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J. Pharmacokinet. Biopharm. 26:207-246.
11. Karlsson, M. O., and L. B. Sheiner. 1993. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J. Pharmacokinet. Biopharm. 21:735-750.
12. Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulation. Antimicrob. Agents Chemother. 44:1734-1736.
13. Marr, K. A., R. A. Carter, F. Crippa, A. Wald, and L. Corey. 2002. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34:909-917.
14. Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, G. V. Doern, M. E. Brandt, and R. A. Hajjeh. 1998. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147. Sch 56592. and voriconazole. Antimicrob. Agents Chemother. 42:3242-3244.
15. Pfizer. 2001. FDA Antiviral Drugs Advisory Committee briefing document for voriconazole (oral and intravenous formulations). FDA, Rockville, MD. http://www.fda.gov/ohrms/dockets/AC/01/briefing/3792b2-01-Pfizer.pdf. Accessed 15 January 2008.
16. Purkins, L., N. Wood, P. Ghahramani, K. Greenhalgh, M. J. Allen, and D. Kleinermans. 2002. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46:2546-2553.
17. Purkins, L., N. Wood, D. Kleinermans, K. Greenhalgh, and D. Nichols. 2003. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br. J. Clin. Pharmacol. 56(Suppl. l):17-23.
18. Purkins, L., N. Wood, K. Greenhalgh, M. J. Allen, and S. D. Oliver. 2003. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br. J. Clin. Pharmacol. 56(Suppl. 1):10-16.
19. Schoemaker, R. C, J. M. van Gerven, and A. F. Cohen. 1998. Estimating potency for the Emax-model without attaining maximal effects. J. Pharmacokinet. Biopharm. 26:581-593.
20. Sheiner, L. B., B. Rosenberg, and V. V. Marathe. 1977. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J. Pharmacokinet. Biopharm. 5:445-479.
21. Sheiner, L. B., and S. L. Beak 1981. Evaluation of methods for estimating population pharmacokinetic parameters, ii. Biexponential model and experimental pharmacokinetic data. J. Pharmacokinet. Biopharm. 9:635-651.
22. Stopher, D. A., and R. Gage. 1997. Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column. J. Chromatogr. B 691:441-448.
23. Walsh, T. J., M. O. Karlsson, T. Driscoll, A. G. Arguedas, P. Adamson, X. Saez-Llorens, A. J. Vora, A. C. Arrieta, J. Blumer, I. Lutsar, P. Milligan, and N. Wood. 2004. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob. Agents Chemother. 48:2166-2172.
24. Wildfeuer, A., H. P. Seidl, I. Paule, and A. Haberreiter. 1998. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole. amphotericin B and griseofulvin. Mycoses 41:309-319.
25. Zaoutis, T. E., K. Heydon, J. H. Chu, T. J. Walsh, and W. J. Steinbach. 2006. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocomopromised children in the United States, 2000. Pediatrics 117:711-716.